Tejnaksh Healthcare Q4 FY26: Margins Recover Amid Revenue Pressures

The quarter's performance reflects a company grappling with structural challenges: net sales contracted 20.56% year-on-year to ₹2.55 crores whilst operating margins improved to 27.84% from 21.81% in the corresponding quarter last year. Following the results announcement, the stock traded at ₹15.24, down 0.65% and sitting 34.62% below its 52-week high of ₹23.31, reflecting investor concerns about the sustainability of the recovery.

The quarter's numbers present a paradox: whilst profitability recovered sequentially, the underlying revenue trajectory remains concerning. Tejnaksh Healthcare operates the Institute of Urology, an ISO-certified speciality hospital in Dhule, Maharashtra, serving a niche market for urological treatments. The company's ability to maintain margins despite revenue pressures suggests improved cost discipline, yet the persistent sales decline raises questions about patient footfall and competitive positioning in the regional healthcare landscape.

Quarterly Performance: Margin Resilience Amid Top-Line Erosion

The quarterly trend reveals a company in transition. Net sales in Q4 FY26 stood at ₹2.55 crores, declining 2.67% quarter-on-quarter and 20.56% year-on-year, marking the third consecutive quarter of year-on-year revenue contraction. The cumulative sales for FY26 quarters tracked thus far suggest an annual revenue run-rate significantly below the ₹12.00 crores achieved in both FY25 and FY24, indicating fundamental challenges in patient acquisition or service utilisation.

Profitability metrics, however, paint a more nuanced picture. Consolidated net profit recovered sharply to ₹0.36 crores in Q4 FY26 from ₹0.30 crores in Q3 FY26, driven by margin expansion rather than revenue growth. Operating margins improved to 27.84% from 26.34% sequentially and from 21.81% in the year-ago quarter, suggesting successful cost rationalisation initiatives. PAT margins similarly expanded to 13.73% from 11.07% in the previous quarter, though they remain below the 17.55%-19.29% range achieved in H2 FY25.

Cost management has clearly been a priority. Employee costs declined to ₹0.31 crores in Q4 FY26 from ₹0.33 crores in Q3 FY26 and ₹0.39 crores in Q4 FY25, indicating workforce optimisation or reduced compensation levels. Interest costs turned negative at -₹0.03 crores in Q4 FY26, suggesting the company may have generated interest income exceeding interest expenses, consistent with its net cash balance sheet position. Depreciation remained stable at ₹0.36 crores, reflecting the capital-intensive nature of hospital operations.

Operational Challenges: Structural Revenue Headwinds Persist

The fundamental challenge facing Tejnaksh Healthcare lies in its inability to sustain revenue growth despite operating in the structurally attractive healthcare services sector. The company's five-year sales growth stands at -0.75% CAGR, whilst EBIT growth has declined at a -5.68% CAGR, indicating deteriorating operational leverage. For a speciality hospital focused on urology in a Tier-2 city, this suggests either market saturation, competitive pressures from larger hospital chains, or challenges in attracting and retaining patients.

Return on equity (ROE) provides insight into capital efficiency. Tejnaksh Healthcare's average ROE of 9.52% and latest ROE of 6.34% place it in the weak performance category for healthcare services companies. Higher ROE indicates better capital efficiency and profitability, and the company's single-digit returns suggest that management has struggled to deploy shareholder capital productively. For context, peer N G Industries achieves a 16.25% ROE, nearly double Tejnaksh's performance, highlighting the operational gap.

The balance sheet, however, reflects financial conservatism. Shareholder funds increased to ₹25.91 crores in FY25 from ₹23.57 crores in FY24, driven by retained earnings. Long-term debt declined sharply to ₹0.63 crores from ₹4.11 crores, resulting in a net debt-to-equity ratio of -0.03, indicating the company is effectively debt-free with net cash. This positions Tejnaksh to weather operational challenges without financial distress, though it also suggests limited appetite for growth investments.

Fixed assets stood at ₹21.16 crores in FY25, down from ₹23.20 crores in FY24, likely reflecting depreciation exceeding capital expenditure. For a hospital operator, this raises questions about facility maintenance and equipment upgrades. Current assets of ₹5.75 crores provide adequate liquidity, with cash flow from operations turning negative at ₹0.00 crores in FY25 compared to positive ₹4.00 crores in FY24, indicating working capital pressures accompanying the revenue decline.

Healthcare Services Sector: Navigating Competitive Intensity

The Indian healthcare services sector presents a tale of two markets: large multi-speciality hospital chains capturing urban demand and smaller speciality hospitals serving niche segments in Tier-2 and Tier-3 cities. Tejnaksh Healthcare operates in the latter category, where competitive dynamics differ markedly from metro markets. The company's focus on urology provides specialisation advantages but also limits addressable market size compared to multi-speciality peers.

Industry tailwinds include rising healthcare awareness, increasing insurance penetration, and growing demand for specialised treatments. However, Tejnaksh's revenue decline suggests these macro trends have not translated into patient growth at its Dhule facility. Potential explanations include: increased competition from larger hospital chains expanding into Tier-2 cities, patient migration to metro hospitals for complex procedures, or reputational challenges affecting patient referrals.

Peer Comparison: Valuation and Performance Benchmarking

Relative to healthcare services peers, Tejnaksh Healthcare presents a mixed valuation picture. Its P/E ratio of 25.38x sits above the peer median but below the industry average of 60x, suggesting the market applies a discount to micro-cap, single-facility operators. The company's P/BV ratio of 1.17x appears reasonable given its 9.52% ROE, though it trades at a premium to book value despite returns below the cost of equity.

The company's superior ROE of 9.52% compared to peers like Deccan Healthcare (1.43%) and GKB Ophthalmics (1.54%) provides some valuation support, though it lags N G Industries' 16.25%. Tejnaksh's net cash position (debt-to-equity of -0.03) mirrors N G Industries and Samsrita Labs, indicating financial conservatism is common among smaller healthcare services players. The absence of dividend yield across most peers suggests these companies prioritise capital retention, though without revenue growth, this strategy's effectiveness remains questionable.

Valuation Analysis: Attractive Entry Point or Value Trap?

At the current price of ₹15.24, Tejnaksh Healthcare trades at a P/E ratio of 25.38x trailing twelve-month earnings, representing a 58% discount to the healthcare services industry average of 60x. The P/BV ratio of 1.17x suggests the market values the company only marginally above its book value of ₹12.76 per share, reflecting scepticism about future earnings growth. For a company with declining revenues and single-digit ROE, this valuation appears neither expensive nor compelling.

The stock's 52-week range of ₹10.65 to ₹23.31 indicates significant volatility, with the current price sitting 43.10% above the low and 34.62% below the high. The company's proprietary Mojo Score of 31/100 and "SELL" rating reflects fundamental concerns outweighing valuation attractions. The valuation grade of "VERY ATTRACTIVE" appears at odds with deteriorating fundamentals, suggesting the low absolute valuation may be justified by poor business quality rather than representing a buying opportunity.

The EV/EBITDA multiple of 10.86x appears reasonable for a healthcare services company, though the declining EBITDA trajectory raises concerns about sustainability. With enterprise value at ₹33.00 crores (approximating market cap given net cash position) and trailing EBITDA around ₹3.00 crores, the company generates modest cash flows relative to its valuation. The EV/Sales ratio of 2.80x suggests the market values each rupee of revenue at ₹2.80, a premium that appears unjustified given negative sales growth.

Shareholding Pattern: Stable Promoter Base, Absent Institutions

The shareholding pattern reveals a tightly held company with zero institutional participation. Promoter holding has remained static at 73.83% across all tracked quarters, with key promoters Ashish Vishwas Rawandale (38.15%) and Preeti Ashish Rawandale (35.53%) maintaining stable stakes. The absence of any pledging provides comfort regarding financial stability, though the lack of stake increases also suggests promoters are not deploying personal capital to support the business during challenging times.

The complete absence of FII, mutual fund, insurance, and other DII holdings (all at 0.00%) is striking and indicative of the company's micro-cap status and liquidity constraints. Institutional investors typically require minimum market capitalisation thresholds (often ₹100-500 crores), governance standards, and liquidity levels that Tejnaksh currently does not meet. The 26.17% non-institutional holding represents retail investors, whose stable participation suggests a loyal but small shareholder base.

Stock Performance: Prolonged Underperformance Against Benchmarks

The stock's performance history reveals consistent and severe underperformance across all meaningful timeframes. Over one year, Tejnaksh Healthcare declined 30.44% whilst the Sensex fell 8.82%, generating negative alpha of -21.62%. More alarmingly, the stock underperformed the healthcare services sector by 49.18 percentage points, with sector returns of +18.74% highlighting that industry tailwinds have bypassed this company entirely.

Longer-term returns paint an even grimmer picture. The three-year return of -55.10% compares to Sensex gains of +18.96%, producing negative alpha of -74.06%. Five-year returns of -49.95% versus Sensex returns of +43.00% indicate fundamental value destruction rather than temporary cyclical weakness. The stock's beta of 1.50 classifies it as high beta, meaning it amplifies market movements—unfortunately, this has meant magnified losses during market corrections without commensurate gains during rallies.

Recent technical indicators provide limited encouragement. The stock trades below all major moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), with the current "MILDLY BEARISH" trend unchanged since May 6, 2026. Delivery volumes increased 39.63% over the trailing one-month period, suggesting some investor accumulation, though the low absolute volumes (1,207 shares traded on June 1, 2026) limit the significance of this metric.

Investment Thesis: Quality Concerns Outweigh Valuation Appeal

The investment thesis for Tejnaksh Healthcare confronts a fundamental dilemma: attractive valuation metrics obscure deteriorating business fundamentals. The "VERY ATTRACTIVE" valuation grade reflects low absolute multiples (P/E of 25.38x, P/BV of 1.17x) that appear cheap on a relative basis. However, the "BELOW AVERAGE" quality grade, "FLAT" financial trend, and "MILDLY BEARISH" technical trend collectively suggest this cheapness reflects poor business quality rather than a mispricing opportunity.

The company's proprietary Mojo Score of 31/100 and "SELL" rating synthesise these conflicting signals, concluding that quality concerns outweigh valuation appeal. Key factors limiting the score include: persistent bearish technical trends, flat financial performance in recent quarters, weak five-year CAGR growth in operating profits (-5.68%), and consistent underperformance against benchmarks over three years. For value investors seeking "cheap" stocks, Tejnaksh presents a cautionary tale about distinguishing value traps from genuine opportunities.

Key Strengths & Risk Factors

Outlook: What Lies Ahead

The forward outlook for Tejnaksh Healthcare hinges on management's ability to arrest revenue decline and demonstrate a credible path to sustainable growth. The company's debt-free balance sheet provides a runway to navigate near-term challenges, but without revenue recovery, even strong margins cannot drive meaningful profit growth. Investors should monitor quarterly revenue trends closely; stabilisation at current levels followed by sequential growth would represent the first positive inflection point in over a year.

For the stock to merit reconsideration, several conditions would need to materialise: (1) two consecutive quarters of sequential revenue growth, (2) sustained operating margins above 25%, (3) ROE improvement toward 12-15% levels, and (4) evidence of institutional investor interest. Until these catalysts emerge, the stock remains a speculative turnaround play rather than a core portfolio holding, with risks outweighing potential rewards for most investors.